Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

THERAGEN ETEX CO.,LTD.

테라젠이텍스066700KOSDAQSector: Pharma & Biotech
₩2,1101.17%Market cap ₩78.4BAs of Aug 31, 2026 close · updated once daily
Market cap
₩78.4B
#862 in KOSDAQ
7.4x
Sector median 16.1x (profitable cos.)
0.56x
Sector median 1.59x
0.0%
Sector median 0.0%
A
Grade A66.8 ptsTop 17% of 2,523 graded stocksMethodology v2.0
Financial strength
60.2/100
Growth momentum
52.2/100
Price attractiveness
89.1/100
Shareholder Return
37.5/100

As of Aug 31, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SACurrentBCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band A with a total score of 66.8 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩1,888High ₩3,315
Latest close
Price change by period
1W
2.30%
1M
3.60%
3M
16.70%
1Y
25.30%

As of the Aug 31, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

60.2/100
How much debt does it carry relative to equity?
61.9%
Sector median 51.6%
Sector lowhighBottom 42.3% in sector
Can it cover what's due within a year?
194.7%
Sector median 191.7%
Sector lowhighTop 48% in sector
How much of revenue becomes profit?
3.8%
Sector median -2.4%
Sector lowhighTop 32.6% in sector
How much did it earn on its own capital?
7.6%
Sector median -4.5%
Sector lowhighTop 20.9% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

52.2/100
How much did revenue grow in a year?
8.8%
Sector median 6.4%
Sector lowhighTop 41.1% in sector
Has it grown steadily over three years?
12.0%
Sector median 4.9%
Sector lowhighTop 26.1% in sector
Did core profits grow in a year?
-18.3%
Sector median 3.6%
Sector lowhighBottom 29.6% in sector
Are core profits higher than three years ago?
-1.3%
Sector median 3.5%
Sector lowhighBottom 46.5% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

89.1/100
Is the price expensive relative to earnings?
7.4x
Sector median P/E of profitable peers 16.1x · 58% loss-making
Sector lowhighTop 7.1% in sector
Is the price expensive relative to book value?
0.56x
Sector median 1.59x
Sector lowhighTop 14.8% in sector

Valuation uses the Aug 31, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
469,056 shares (1.2% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 1, 2026

Of 9 items: 7 met · 2 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩10.6B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩11B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Met
-16.9% → 4.5%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
₩11B vs ₩10.6B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
44.9% → 38.2%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
150.1% → 194.7%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
32,474,435 → 37,152,376
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
5.0% → 3.8%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Met
1.03x → 1.15x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026A

Methodology version change (v2.0 applied)

Jul 15, 2026AVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Large paid-in capital increase resolved

Disclosed a paid-in capital increase (제3자배정증자) issuing 4,677,941 new shares, equal to 14.4% of shares outstanding before the increase (filed 2025-03-24). View filing ↗

CB with conversion-price adjustment clause (past 36 months)

1 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2025-04-10). View filing ↗

Determined as of 2026-09-01

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →